WO2016159897A1 - Potassium citrate suspension - Google Patents
Potassium citrate suspension Download PDFInfo
- Publication number
- WO2016159897A1 WO2016159897A1 PCT/TR2015/000136 TR2015000136W WO2016159897A1 WO 2016159897 A1 WO2016159897 A1 WO 2016159897A1 TR 2015000136 W TR2015000136 W TR 2015000136W WO 2016159897 A1 WO2016159897 A1 WO 2016159897A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- suspension according
- potassium citrate
- pharmaceutical
- pharmaceutical suspension
- sodium
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
Definitions
- Potassium citrate alkalinizes the urine and reduces the formation of the two most common types of kidney stones: calcium oxalate and uric acid stones.
- the objective of treatment with Potassium Citrate is to restore normal urinary citrate (greater than 320 mg/day and as close to the normal mean of 640 mg/day as possible), and to increase urinary pH to a level of 6 or 7.
- potassium citrate helps relieve symptoms of cystitis and other mild urinary infections. It works by making urine less acidic and this helps relieve the discomfort caused by the infection.
- the citrate moiety which is largely oxidized, is absorbed while the K ion remains, leaving an alkali load.
- the alkali load increases urinary citrate and urinary pH. As a result, it decreases urinary saturation of calcium oxalate and inhibits both calcium oxalate and its crystallization.
- compositions comprising potassium citrate is indicated for the management of renal tubuiar acidosis (RTA) with calcium stones, hypocitraturic calcium oxalate nephrolithiasis of any etiology, and uric acid lithiasis with or without calcium stones.
- RTA renal tubuiar acidosis
- Potassium citrate is a potassium salt of citric acid with the molecular formula C 6 H 5 K 3 O 7 . Molecular weight is 306,39 g/mol.
- Potassium citrate monohydrate is white crystals, granules or powder. One gram dissolves in 0.65 ml water. The pH of aqueous solution is about 8.5.
- potassium citrate 10 mEq equals 1080mg and 15mEq equals 1620mg of potassium citrate monohydrate.
- US4888182 and US4966776 relate to methods and compositions for the treatment and prophylaxis of calcium renal stones by administering the patient a daily oral dosage of a composition consisting essentially of potassium citrate.
- the daily oral dosage of potassium citrate is between about 30 meq and about 120 meq.
- a typical dosage scheme involves administering about 30 to 120 meq potassium citrate per day in divided doses.
- Such treatments are effective in dissolving existing calcium stones and preventing formation of new calcium stones.
- the potassium citrate is superior to sodium citrate in the treatment of uric acid lithiasis. Potassium citrate therapy averts calcium renal stone formation, a complication which is often associated with sodium citrate or sodium bicarbonate alkalinization therapy.
- CYTRA-3 Syrup contains Potassium Citrate Monohydrate 550 mg, Sodium Citrate Dihydrate 500 mg and Citric Acid Monohydrate 334 mg in each teaspoonful (5 ml_). Each 5 ml_ contains 1 mEq potassium ion and 1 mEq sodium ion and is equivalent to 2 mEq bicarbonate (HC03). This product alkalinizes the urine.
- Mission Pharmacal sells an extended-release potassium citrate tablet, Urocit-K, in three strengths: 5 -mEq, 10-meq, and 15- mEq tablets.
- the daily dose of Urocit-K is 30-60 mEq.
- Urocit-K is a wax matrix tablet containing potassium citrate, carnauba wax as extended-release agent, and magnesium stearate as lubricant.
- US 4,904,478 teaches an extended-release wax matrix tablet of a highly water-soluble drug, sodium fluoride, wherein the carnauba wax, present at 35-70% w/w of the tablet weight, is dry mixed with the drug and other inactive ingredients prior to compression.
- the inactive ingredients including the extended-release agent(s) must be kept below 25% w/w to keep the tablet size acceptable for swallowing. If carnauba wax is used at less than 25% w/w, Example 1 of US 2008/0131504 A! discloses that the drug and carnauba wax should be heated until the carnauba wax liquefies, to give an acceptable extended-release profile and abrasion.
- WO 2014051443 relates to the extended-release potassium citrate tablets containing carnauba wax can be produced without melting the wax.
- the present invention provides a pharmaceutical oral suspension composition comprising potassium citrate for the treatment and prophylaxis of calcium renal stones in persons susceptible to such stone formations.
- potassium citrate and potassium citrate monohydrate describes same compound.
- the present invention relates to manufacture a pharmaceutical oral suspension form of high dosage potassium citrate having improved physico-chemical properties so that their use by patients.
- the pharmaceutical oral suspension comprises potassium citrate monohydrate between 540mg (5mEq) and 2160mg (20mEq) in 5ml, preferably 216Gmg (20mEq) in 5ml.
- a stable and easily pourable pharmaceutical composition prepares in the form of a suspension comprising potassium citrate.
- the suspensions suitable for oral administration are aqueous-based.
- an organic co- solvent it is preferred that it is used in amounts of 0.5 to 10% (g/ml) of the total composition.
- Suitable solvents are those water-miscible solvents commonly used in the art, e. g., glycerol, propylene glycol (1 ,2-propane dio!), polyethylene glycol 300, polyethylene glycol 400 and ethanol.
- glycerol is selected as co-solvent in the composition.
- Oral suspensions according to the invention may contain other exctpients commonly employed in oral suspensions in order to provide the required stability and therapeutic efficacy.
- Suspending agents can be any convenient agents known in the art for this purpose.
- the composition comprises at least one compound selected from the group consisting of xanthan gum, guar gum, hydroxypropylmethyl cellulose, hydroxypropyi cellulose, methylceilulose, hydroxyethylcellulose, polyvinyl pyrrolidone, alginates, acacia, tragacanth, carboxylmethylcellulose and sodium carboxylmethyice!lu!ose (Na CMC).
- Suspending agents may be employed in an amount within the range from about 0 to about 20% by weight of the powder formulation, and from about 0 to about 10% by weight of the oral suspension.
- Sweeteners for use in the formulations of the invention may be any convenient agents known in the art for this purpose and may be selected from any compatible sweetener groups such as natural sweeteners like sucrose, fructose, dextrose, maltose, mannose, galactose, xylitol, sorbitol, or mannitol, glycerin as well as artificial sweeteners such as sodium cyclamate, sodium saccharin aspartame, acesulfam K and sucraiose.
- the composition comprises at least one sweetener.
- sucraiose is used as sweetener.
- Flavors and flavor modifiers or taste modifiers can also be used to further improve the taste and can be any convenient agents known in the art for this purpose and include, but are not limited to, orange flavor, vanilla flavor, licorice flavor, orange vanilla flavor, creme de mint, cherry flavor, cherry vanilla flavor, berry mix flavor, mandarin orange flavor and tutti-frutti- flavor, and combinations thereof.
- the composition comprises at least one flavoring or taste modifier. Preferably, orange flavor is used.
- Preservatives can be any convenient agents known in the art for this purpose such as methy!paraben and propylparaben, benzoic acid, sodium benzoate, potassium sorbate.
- the composition comprises at least one preservative.
- preservative agent used is mixture of methylparaben sodium and propylparaben sodium.
- wetting agents can be used in the composition such as polyethylene glycol stearates, (polyethylene glycol 400 monostearate), Poloxamer, Polysorbates.
- Glidants can also optionally be used such as silicon dioxide, talc and titanium dioxide.
- Methylparaben sodium, propylparaben sodium, potassium citrate, sucralose and Xanthan gum are dissolved in deionized water for preparing a palatable suspension with drug concentration of 20mEq/5 ml of potassium citrate. Glycerol and orange oil are added. Then the volume is completed with water and it is filled into glass or plastic (HDPE) 250 ml bottles for desired fill weight.
- HDPE glass or plastic
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to the oral suspension comprising potassium citrate monohydrate between 540mg (5mEq) and 2160mg (20mEq) in 5ml for the treatment and prophylaxis of renal stones.
Description
POTASSIUM CITRATE SUSPENSION
DESCRIPTION
Potassium citrate alkalinizes the urine and reduces the formation of the two most common types of kidney stones: calcium oxalate and uric acid stones. The objective of treatment with Potassium Citrate is to restore normal urinary citrate (greater than 320 mg/day and as close to the normal mean of 640 mg/day as possible), and to increase urinary pH to a level of 6 or 7.
Also, potassium citrate helps relieve symptoms of cystitis and other mild urinary infections. It works by making urine less acidic and this helps relieve the discomfort caused by the infection.
The citrate moiety, which is largely oxidized, is absorbed while the K ion remains, leaving an alkali load. The alkali load increases urinary citrate and urinary pH. As a result, it decreases urinary saturation of calcium oxalate and inhibits both calcium oxalate and its crystallization.
Pharmaceuticals comprising potassium citrate is indicated for the management of renal tubuiar acidosis (RTA) with calcium stones, hypocitraturic calcium oxalate nephrolithiasis of any etiology, and uric acid lithiasis with or without calcium stones.
Potassium citrate is a potassium salt of citric acid with the molecular formula C6H5K3O7. Molecular weight is 306,39 g/mol.
Potassium citrate monohydrate is white crystals, granules or powder. One gram dissolves in 0.65 ml water. The pH of aqueous solution is about 8.5.
5 mEq equals 540mg of potassium citrate monohydrate. Also potassium citrate 10 mEq equals 1080mg and 15mEq equals 1620mg of potassium citrate monohydrate.
US4888182 and US4966776 relate to methods and compositions for the treatment and prophylaxis of calcium renal stones by administering the patient a daily oral dosage of a composition consisting essentially of potassium citrate. The daily oral dosage of potassium citrate is between about 30 meq and about 120 meq.
A typical dosage scheme involves administering about 30 to 120 meq potassium citrate per day in divided doses. Such treatments are effective in dissolving existing calcium stones and preventing formation of new calcium stones. Moreover, the potassium citrate is superior to sodium citrate in the treatment of uric acid lithiasis. Potassium citrate therapy averts calcium renal stone formation, a complication which is often associated with sodium citrate or sodium bicarbonate alkalinization therapy.
CYTRA-3 Syrup contains Potassium Citrate Monohydrate 550 mg, Sodium Citrate Dihydrate 500 mg and Citric Acid Monohydrate 334 mg in each teaspoonful (5 ml_). Each 5 ml_ contains 1 mEq potassium ion and 1 mEq sodium ion and is equivalent to 2 mEq bicarbonate (HC03). This product alkalinizes the urine.
Mission Pharmacal (San Antonio, TX, USA) sells an extended-release potassium citrate tablet, Urocit-K, in three strengths: 5 -mEq, 10-meq, and 15- mEq tablets. The daily dose of Urocit-K is 30-60 mEq. Urocit-K is a wax matrix tablet containing potassium citrate, carnauba wax as extended-release agent, and magnesium stearate as lubricant.
US 4,904,478 teaches an extended-release wax matrix tablet of a highly water-soluble drug, sodium fluoride, wherein the carnauba wax, present at 35-70% w/w of the tablet weight, is dry mixed with the drug and other inactive ingredients prior to compression. In the case of potassium citrate, because the drug dosage is high, the inactive ingredients including the extended-release agent(s) must be kept below 25% w/w to keep the tablet size acceptable for swallowing. If carnauba wax is used at less than 25% w/w, Example 1 of US 2008/0131504 A! discloses that the drug and carnauba wax should be heated until the carnauba wax liquefies, to give an acceptable extended-release profile and abrasion.
WO 2014051443 relates to the extended-release potassium citrate tablets containing carnauba wax can be produced without melting the wax.
SUMMARY OF THE INVENTION
The present invention provides a pharmaceutical oral suspension composition comprising potassium citrate for the treatment and prophylaxis of calcium renal stones in persons susceptible to such stone formations. (The terms of potassium citrate and potassium citrate monohydrate describes same compound.)
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to manufacture a pharmaceutical oral suspension form of high dosage potassium citrate having improved physico-chemical properties so that their use by patients.
The pharmaceutical oral suspension comprises potassium citrate monohydrate between 540mg (5mEq) and 2160mg (20mEq) in 5ml, preferably 216Gmg (20mEq) in 5ml.
According to the present invention, a stable and easily pourable pharmaceutical composition prepares in the form of a suspension comprising potassium citrate.
The suspensions suitable for oral administration are aqueous-based. When an organic co- solvent is employed it is preferred that it is used in amounts of 0.5 to 10% (g/ml) of the total composition. Suitable solvents are those water-miscible solvents commonly used in the art, e. g., glycerol, propylene glycol (1 ,2-propane dio!), polyethylene glycol 300, polyethylene glycol 400 and ethanol. Preferably, glycerol is selected as co-solvent in the composition.
Oral suspensions according to the invention may contain other exctpients commonly employed in oral suspensions in order to provide the required stability and therapeutic efficacy.
Suspending agents can be any convenient agents known in the art for this purpose. The composition comprises at least one compound selected from the group consisting of xanthan gum, guar gum, hydroxypropylmethyl cellulose, hydroxypropyi cellulose, methylceilulose, hydroxyethylcellulose, polyvinyl pyrrolidone, alginates, acacia, tragacanth, carboxylmethylcellulose and sodium carboxylmethyice!lu!ose (Na CMC). Suspending agents may be employed in an amount within the range from about 0 to about 20% by weight of the powder formulation, and from about 0 to about 10% by weight of the oral suspension.
Sweeteners for use in the formulations of the invention may be any convenient agents known in the art for this purpose and may be selected from any compatible sweetener groups such as natural sweeteners like sucrose, fructose, dextrose, maltose, mannose, galactose, xylitol, sorbitol, or mannitol, glycerin as well as artificial sweeteners such as sodium cyclamate, sodium saccharin aspartame, acesulfam K and sucraiose. The composition comprises at least one sweetener. Preferably, sucraiose is used as sweetener.
Flavors and flavor modifiers or taste modifiers can also be used to further improve the taste and can be any convenient agents known in the art for this purpose and include, but are not limited to, orange flavor, vanilla flavor, licorice flavor, orange vanilla flavor, creme de mint, cherry flavor, cherry vanilla flavor, berry mix flavor, mandarin orange flavor and tutti-frutti- flavor, and combinations thereof. The composition comprises at least one flavoring or taste modifier. Preferably, orange flavor is used.
Preservatives can be any convenient agents known in the art for this purpose such as methy!paraben and propylparaben, benzoic acid, sodium benzoate, potassium sorbate. The composition comprises at least one preservative. Preferably, preservative agent used is mixture of methylparaben sodium and propylparaben sodium.
Also wetting agents can be used in the composition such as polyethylene glycol stearates, (polyethylene glycol 400 monostearate), Poloxamer, Polysorbates.
Glidants can also optionally be used such as silicon dioxide, talc and titanium dioxide..
Methylparaben sodium, propylparaben sodium, potassium citrate, sucralose and Xanthan gum are dissolved in deionized water for preparing a palatable suspension with drug concentration of 20mEq/5 ml of potassium citrate. Glycerol and orange oil are added. Then the volume is completed with water and it is filled into glass or plastic (HDPE) 250 ml bottles for desired fill weight.
Example 1:
Claims
1. A pharmaceutical oral suspension comprising potassium citrate wherein the amount of potassium citrate monohydrate in 5ml is between 540mg (5mEq) and 2160mg (20mEq).
2. A pharmaceutical oral suspension according to claim 1 wherein the amount of potassium citrate monohydrate in 5ml is 2160mg (20mEq).
3. A pharmaceutical suspension according to claim 1-2 wherein it comprises at least one compound selected from the group consisting of xanthan gum, guar gum, hydroxypropylmethyi cellulose, hydroxypropyi cellulose, methylcellulose, hydroxyethylcellulose, polyvinyl pyrroiidone, alginates, Acacia, Tragacanth, carboxylmethy!cel!u!ose and sodium carboxylmethylcellulose (Na CMC) as suspending agents.
4. A pharmaceutical suspension according to claim 3 wherein suspending agent is xanthan gum.
5. A pharmaceutical suspension according to claim 4 wherein the amount of xanthan gum is from 0.05 to 2 grams in 100 ml of suspension.
6. A pharmaceutical suspension according to claims 1-5 wherein it comprises at least one co-solvent.
7. A pharmaceutical suspension according to claim 6 wherein co-solvent is glycerol.
8. A pharmaceutical suspension according to claims 1-7 wherein it comprises at least one sweetening agent.
9. A pharmaceutical suspension according to claim 8 wherein sweeting agent is sucralose.
10. A pharmaceutical suspension according to claims 1-9 wherein it comprises at least one preservative agent.
11. A pharmaceutical suspension according to claim 10 wherein preservative agent is mixture of methylparaben sodium and propylparaben sodium.
12. A pharmaceutical suspension according to previous claims wherein it uses for the treatment and preventing the formation of the kidney stones.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/TR2015/000136 WO2016159897A1 (en) | 2015-04-01 | 2015-04-01 | Potassium citrate suspension |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/TR2015/000136 WO2016159897A1 (en) | 2015-04-01 | 2015-04-01 | Potassium citrate suspension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2016159897A1 true WO2016159897A1 (en) | 2016-10-06 |
Family
ID=53039559
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/TR2015/000136 WO2016159897A1 (en) | 2015-04-01 | 2015-04-01 | Potassium citrate suspension |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2016159897A1 (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11395931B2 (en) | 2017-12-02 | 2022-07-26 | Mighty Fire Breaker Llc | Method of and system network for managing the application of fire and smoke inhibiting compositions on ground surfaces before the incidence of wild-fires, and also thereafter, upon smoldering ambers and ashes to reduce smoke and suppress fire re-ignition |
| US11400324B2 (en) | 2017-12-02 | 2022-08-02 | Mighty Fire Breaker Llc | Method of protecting life, property, homes and businesses from wild fire by proactively applying environmentally-clean anti-fire (AF) chemical liquid spray in advance of wild fire arrival and managed using a wireless network with GPS-tracking |
| US11826592B2 (en) | 2018-01-09 | 2023-11-28 | Mighty Fire Breaker Llc | Process of forming strategic chemical-type wildfire breaks on ground surfaces to proactively prevent fire ignition and flame spread, and reduce the production of smoke in the presence of a wild fire |
| US11865390B2 (en) | 2017-12-03 | 2024-01-09 | Mighty Fire Breaker Llc | Environmentally-clean water-based fire inhibiting biochemical compositions, and methods of and apparatus for applying the same to protect property against wildfire |
| US11865394B2 (en) | 2017-12-03 | 2024-01-09 | Mighty Fire Breaker Llc | Environmentally-clean biodegradable water-based concentrates for producing fire inhibiting and fire extinguishing liquids for fighting class A and class B fires |
| US11911643B2 (en) | 2021-02-04 | 2024-02-27 | Mighty Fire Breaker Llc | Environmentally-clean fire inhibiting and extinguishing compositions and products for sorbing flammable liquids while inhibiting ignition and extinguishing fire |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4888182A (en) | 1983-04-11 | 1989-12-19 | Board Of Regents Of The University Of Texas System | Compositions and methods of treating calcium renal stones |
| US4904478A (en) | 1983-08-11 | 1990-02-27 | Mission Pharmacal Company | Slow-release sodium fluoride tablet and method for treatment of osteoporosis |
| US4966776A (en) | 1983-04-11 | 1990-10-30 | Board Of Regents, The University Of Texas System | Compositions and methods of treating calcium renal stones |
| US5759579A (en) * | 1996-12-05 | 1998-06-02 | American Home Products Corporation | Pharmaceutical suspension systems |
| WO2007011740A2 (en) * | 2005-07-15 | 2007-01-25 | Mission Pharmacal Co. | A powder mix of potassium calcium citrate for the treatment of kidney stones and osteoporosis |
| US20080131504A1 (en) | 2006-12-01 | 2008-06-05 | Mission Pharmacal Co. | Short Term Slow Release Drug Delivery System |
| WO2014051443A1 (en) | 2012-09-27 | 2014-04-03 | Mendoza Wendell G | Method for producing extended-release potassium citrate wax matrix tablet |
| US20140271929A1 (en) * | 2013-03-15 | 2014-09-18 | New York University | Citrate containing beverage |
-
2015
- 2015-04-01 WO PCT/TR2015/000136 patent/WO2016159897A1/en active Application Filing
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4888182A (en) | 1983-04-11 | 1989-12-19 | Board Of Regents Of The University Of Texas System | Compositions and methods of treating calcium renal stones |
| US4966776A (en) | 1983-04-11 | 1990-10-30 | Board Of Regents, The University Of Texas System | Compositions and methods of treating calcium renal stones |
| US4904478A (en) | 1983-08-11 | 1990-02-27 | Mission Pharmacal Company | Slow-release sodium fluoride tablet and method for treatment of osteoporosis |
| US5759579A (en) * | 1996-12-05 | 1998-06-02 | American Home Products Corporation | Pharmaceutical suspension systems |
| WO2007011740A2 (en) * | 2005-07-15 | 2007-01-25 | Mission Pharmacal Co. | A powder mix of potassium calcium citrate for the treatment of kidney stones and osteoporosis |
| US20080131504A1 (en) | 2006-12-01 | 2008-06-05 | Mission Pharmacal Co. | Short Term Slow Release Drug Delivery System |
| WO2014051443A1 (en) | 2012-09-27 | 2014-04-03 | Mendoza Wendell G | Method for producing extended-release potassium citrate wax matrix tablet |
| US20140271929A1 (en) * | 2013-03-15 | 2014-09-18 | New York University | Citrate containing beverage |
Non-Patent Citations (2)
| Title |
|---|
| ANONYMOUS: "tricitrates", July 2012 (2012-07-01), XP002740483, Retrieved from the Internet <URL:http://www.drugs.com/pro/tricitrates.html> * |
| CHARLES Y C PAK ET AL: "Augmentation of RenalCitrateExcretionby OralPotassium CitrateAdministration: TimeCourse, DoseFrequency Schedule, and Dose-Response Relatiooship", THE JOURNAL OF CLINICAL PHARMACOLOGY, vol. 24, 7 March 2013 (2013-03-07), pages 19 - 26, XP055193525, ISSN: 0091-2700 * |
Cited By (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11697039B2 (en) | 2017-12-02 | 2023-07-11 | Mighty Fire Breaker Llc | Wireless communication network, GPS-tracked back-pack spraying systems and command center configured for proactively spraying environmentally-safe anti-fire chemical liquid on property surfaces to inhibit fire ignition and flame spread in the presence of wild fire |
| US11642555B2 (en) | 2017-12-02 | 2023-05-09 | Mighty Fire Breaker Llc | Wireless wildfire defense system network for proactively defending homes and neighborhoods against wild fires by spraying environmentally-clean anti-fire chemical liquid on property and buildings and forming GPS-tracked and mapped chemical fire breaks about the property |
| US11395931B2 (en) | 2017-12-02 | 2022-07-26 | Mighty Fire Breaker Llc | Method of and system network for managing the application of fire and smoke inhibiting compositions on ground surfaces before the incidence of wild-fires, and also thereafter, upon smoldering ambers and ashes to reduce smoke and suppress fire re-ignition |
| US11638844B2 (en) | 2017-12-02 | 2023-05-02 | Mighty Fire Breaker Llc | Method of proactively protecting property from wild fire by spraying environmentally-clean anti-fire chemical liquid on property surfaces prior to wild fire arrival using remote sensing and GPS-tracking and mapping enabled spraying |
| US11697040B2 (en) | 2017-12-02 | 2023-07-11 | Mighty Fire Breaker Llc | Wild fire defense system network using a command center, spraying systems and mobile computing systems configured to proactively defend homes and neighborhoods against threat of wild fire by spraying environmentally-safe anti-fire chemical liquid on property surfaces before presence of wild fire |
| US11654313B2 (en) | 2017-12-02 | 2023-05-23 | Mighty Fire Breaker Llc | Wireless communication network, GPS-tracked ground-based spraying tanker vehicles and command center configured for proactively spraying environmentally-safe anti-fire chemical liquid on property surfaces to inhibit fire ignition and flame spread in the presence of wild fire |
| US11654314B2 (en) | 2017-12-02 | 2023-05-23 | Mighty Fire Breaker Llc | Method of managing the proactive spraying of environment ally-clean anti-fire chemical liquid on GPS-specified property surfaces so as to inhibit fire ignition and flame spread in the presence of wild fire |
| US11707639B2 (en) | 2017-12-02 | 2023-07-25 | Mighty Fire Breaker Llc | Wireless communication network, GPS-tracked mobile spraying systems, and a command system configured for proactively spraying environmentally-safe anti-fire chemical liquid on combustible property surfaces to protect property against fire ignition and flame spread in the presence of wild fire |
| US11633636B2 (en) | 2017-12-02 | 2023-04-25 | Mighty Fire Breaker Llc | Wireless neighborhood wildfire defense system network supporting proactive protection of life and property in a neighborhood through GPS-tracking and mapping of environmentally-clean anti-fire (AF) chemical liquid spray applied to the property before wild fires reach the neighborhood |
| US11400324B2 (en) | 2017-12-02 | 2022-08-02 | Mighty Fire Breaker Llc | Method of protecting life, property, homes and businesses from wild fire by proactively applying environmentally-clean anti-fire (AF) chemical liquid spray in advance of wild fire arrival and managed using a wireless network with GPS-tracking |
| US11697041B2 (en) | 2017-12-02 | 2023-07-11 | Mighty Fire Breaker Llc | Method of proactively defending combustible property against fire ignition and flame spread in the presence of wild fire |
| US11730987B2 (en) | 2017-12-02 | 2023-08-22 | Mighty Fire Breaker Llc | GPS tracking and mapping wildfire defense system network for proactively defending homes and neighborhoods against threat of wild fire by spraying environmentally-safe anti-fire chemical liquid on property surfaces to inhibit fire ignition and flame spread in the presence of wild fire |
| US11794044B2 (en) | 2017-12-02 | 2023-10-24 | Mighty Fire Breaker Llc | Method of proactively forming and maintaining GPS-tracked and mapped environmentally-clean chemical firebreaks and fire protection zones that inhibit fire ignition and flame spread in the presence of wild fire |
| US11865390B2 (en) | 2017-12-03 | 2024-01-09 | Mighty Fire Breaker Llc | Environmentally-clean water-based fire inhibiting biochemical compositions, and methods of and apparatus for applying the same to protect property against wildfire |
| US11865394B2 (en) | 2017-12-03 | 2024-01-09 | Mighty Fire Breaker Llc | Environmentally-clean biodegradable water-based concentrates for producing fire inhibiting and fire extinguishing liquids for fighting class A and class B fires |
| US11826592B2 (en) | 2018-01-09 | 2023-11-28 | Mighty Fire Breaker Llc | Process of forming strategic chemical-type wildfire breaks on ground surfaces to proactively prevent fire ignition and flame spread, and reduce the production of smoke in the presence of a wild fire |
| US11911643B2 (en) | 2021-02-04 | 2024-02-27 | Mighty Fire Breaker Llc | Environmentally-clean fire inhibiting and extinguishing compositions and products for sorbing flammable liquids while inhibiting ignition and extinguishing fire |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2016159897A1 (en) | Potassium citrate suspension | |
| KR102218334B1 (en) | Enhanced stability of novel liquid compositions | |
| ES2259098T3 (en) | COMPOSITIONS THAT INCLUDE IPATROPY AND XYLOMETAZOLINE FOR THE TREATMENT OF THE COMMON COLD. | |
| JP2004535370A (en) | Liquid pharmaceutical composition with masked taste | |
| EP3003384B1 (en) | Oral solution comprising atomoxetine hydrochloride | |
| US11529333B2 (en) | Oral pharmaceutical composition comprising zonisamide and process of preparation thereof | |
| US20090048344A1 (en) | Pharmaceutical composition comprising 5-methyl-2-2' (chloro-6'-fluoroanilino phe nylacetic acid | |
| US20130109729A1 (en) | Pharmaceutical composition | |
| US20060269598A1 (en) | Antihistaminic/Decongestant/Anticholinergic Compositions and Methods of Use | |
| KR20200121835A (en) | Multi-use Torasemide Composition | |
| US20060269597A1 (en) | Tannate Compositions and Methods of Use for the Treatment of Respiratory Tract Conditions | |
| WO2014191414A1 (en) | Syrup formulation of salbutamol | |
| US20060100271A1 (en) | Stabilized aqueous ranitidine compositions | |
| EP1374874B1 (en) | Liquid antacid compositions | |
| US20070248667A1 (en) | Tannate Compositions and Methods of Use | |
| EP3678498B1 (en) | Composition for calcium supplementation | |
| US20230082870A1 (en) | Composition for calcium supplementation | |
| AU2008321159B2 (en) | Liquid compositions comprising valsartan | |
| AU2002329578B2 (en) | Compositions for treatment of common cold | |
| EP1001763A1 (en) | Aqueous compositions comprising ranitidine and lcmt sucrose | |
| WO2008039792A1 (en) | Stable pharmaceutical compositions of preserved formulation of ranitidine, process for making the same, and methods of their use | |
| AU2002329578A1 (en) | Compositions for treatment of common cold |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15719871 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 15719871 Country of ref document: EP Kind code of ref document: A1 |